Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ASPH | Q12797 | 1/20 | 0.34 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14398518 | 0.86 | KMT2A (0.41) | KMT2ATSHRKDM4EMAPT | |
| SCHEMBL17757467 | 0.86 | KMT2A (0.41) | KMT2ATSHRKDM4EMAPT | |
| SCHEMBL17757653 | 0.86 | KMT2A (0.41) | KMT2ATSHRKDM4EMAPT | |
| SCHEMBL17757634 | 0.85 | KMT2A (0.39) | KMT2ATSHRKDM4EMAPT | |
| SCHEMBL17757164 | 0.83 | KMT2A (0.39) | KMT2ATSHRALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL17757640 | 0.81 | ACHE (0.38) | KMT2ATSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL17757632 | 0.81 | ACHE (0.38) | KMT2ATSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL17757162 | 0.81 | EGFR (0.38) | KMT2ATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL17757157 | 0.81 | EGFR (0.38) | KMT2ATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL17757643 | 0.81 | KMT2A (0.40) | KMT2ATSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| WO-2016075137-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | KMT2A 4518/4885TSHR 1100/4885LMNA 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.